Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Vertex Pharmaceuticals received an upgrade from StockNews.com, moving from a “hold” to a “buy” rating. Other analysts have ...

This was the stock's second consecutive day of gains.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $495.29, marking a +1.42% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.49%.